How We Treat Myeloproliferative Neoplasms

Successful CAR-T cell treatment of aggressive B-cell lymphoma associated with a myeloproliferative disorder treated with a JAK1/2 inhibitor

“…The patient was diagnosed with JAK2 positive essential thrombocythemia (ET) in 2009 at the age of 35. In accordance with current guidelines, treatment with hydroxyurea was initiated [4]. After two months, this treatment was replaced by PEGylated interferon-α (Pegasys ® ) in January 2010.…”